AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

BioCapital

Vantage Report 2018: Research Dragged, but Biotech IPOs and Startups Soared

Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.

February 28, 2019

5 min read

Mark Terry

Policy

Gang of 7 Pharma Execs Grilled by Congress

U.S. Senator Chuck Grassley (R-Iowa) set the tone early, mentioning his constituents rationing drugs because of high prices or “leaving their prescription on the pharmacy counter because it costs too much,” but acknowledging that innovations “take time and money.”

February 26, 2019

4 min read

Mark Terry

Business

Voyager and AbbVie Forge Another Neurodegenerative Therapy Collaboration Worth More Than $1 Billion

Voyager Therapeutics struck a deal with Illinois-based AbbVie to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease.

February 22, 2019

2 min read

Alex Keown

Deals

Firmly on our way to becoming a fully integrated biopharma company

FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability

February 21, 2019

12 min read

Policy

AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa

AbbVie announced that they have received approval for an additional indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa.

February 21, 2019

5 min read

Bio NC

J&J Earns Spot in Fortune’s Top 50 Most Respected Companies

It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.

February 21, 2019

4 min read

Alex Keown

Policy

Meet the Pharma Reps About to Face the Senate Over Pricing Concerns

Seven pharma executives will enter the Congressional crucible next week as they face questions and concerns over the rising costs of prescription drugs.

February 21, 2019

3 min read

Alex Keown

BioCapital

House Ways and Means Committee Holds Hearing on Drug Prices

Lawmakers continue to hear concerns over drug prices, as well as proposals to fix the issue.

February 13, 2019

3 min read

Alex Keown

Business

AbbVie Partners With Teneobio, Secures Spot in BCMA Race to Treat Multiple Myeloma

AbbVie is taking a $90 million plunge into B-cell maturation antigen (BCMA)-targeting immunotherapeutics against multiple myeloma in a collaborative deal with Menlo Park, Calif.-based Teneobio, Inc.

February 11, 2019

2 min read

Alex Keown

JOBS